within Pharmacolibrary.Drugs.ATC.B;

model B06AX04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.73,
    Cl             = 0.07483333333333334,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.044700000000000004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0045000000000000005,
    Tlag           = 19.8
  );

  annotation(Documentation(
    info ="<html><body><p>Mitapivat is a first-in-class, oral pyruvate kinase activator used in the treatment of hemolytic anemia in adults with pyruvate kinase deficiency. It is an approved drug, notably by the FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed following single and multiple oral doses in healthy adult volunteers, both male and female.</p><h4>References</h4><ol><li><p>Iyer, V, et al., &amp; Hawkins, P (2024). Relative Bioavailability Studies With Mitapivat: Formulation and Food Effect Assessments in Healthy Subjects. <i>Clinical pharmacology in drug development</i> 13(12) 1271–1282. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1481&quot;>10.1002/cpdd.1481</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39453402/&quot;>https://pubmed.ncbi.nlm.nih.gov/39453402</a></p></li><li><p>Prakash, C, et al., &amp; Iyer, V (2023). An innovative phase I study in healthy subjects to determine the mass balance, elimination, metabolism, and absolute bioavailability of mitapivat. <i>Clinical and translational science</i> 16(10) 2021–2032. DOI:<a href=&quot;https://doi.org/10.1111/cts.13609&quot;>10.1111/cts.13609</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37596712/&quot;>https://pubmed.ncbi.nlm.nih.gov/37596712</a></p></li><li><p>Yang, H, et al., &amp; Barbier, AJ (2019). Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers. <i>Clinical pharmacology in drug development</i> 8(2) 246–259. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.604&quot;>10.1002/cpdd.604</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30091852/&quot;>https://pubmed.ncbi.nlm.nih.gov/30091852</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B06AX04;
